DxCon is the leading forum for advanced diagnostics reimbursement
Join our next gathering
in Napa, CA - October 9-10, 2025
Attended by executive thought leaders and innovative companies, the 2025 DxCon feature a lineup of experts from payers, leading diagnostics companies and firms working to advance the industry.
In parallel to the main conference, exclusive panels with payer medical directors, are open on a first-come basis to companies seeking an unmatched opportunity to learn about reimbursement direct from the source.
About DxCon
Advancing Market Access for Diagnostics
DxCON IS THE PREMIER VENUE FOR THOUGHT LEADERS AND EXECUTIVES in personalized medicine seeking to successfully launch and grow new diagnostics. Hosted by AccessDx®, participants bring perspectives from leading diagnostic companies, pharmaceutical manufacturers, payers, and other stakeholders.
The 2025 edition will explore the rise of companion diagnostics and how pharma and diagnostics companies can collaborate to increase opportunities in a growing market.
Attendees will build their networks with decision makers in interactive professional and social settings,and come away better equipped to address opportunities and challenges in the diagnostics marketplace.
DxCon is ideal for executives from diagnostics and pharmaceutical manufacturers, as well as Medical Directors, Reimbursement Directors, Case Managers, Sales and Marketing Directors, and leaders from other healthcare organizations with a strategic investment in diagnostics.
Registration Rate:
$1,895 - Early Bird
$2,195 - Standard Rate
Please contact us for Group Discounts.
ACCOMMODATIONS: A block of hotel rooms and reservations for DxCon is available to book online here.
”The DxConference discussions were immediately applicable to our team.“
Vice President, Market Access
Delivering on the Promise of Personalized Medicine®
We believe that personalized medicine is talked about a lot but not done enough. We have gathered industry leaders to assist you (diagnostic innovators and manufacturers) in successfully launching personalized medicine diagnostics (PMDx) in the United States.
